Q1 Earnings Estimate for Compugen Issued By HC Wainwright

Compugen Ltd. (NASDAQ:CGEN) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Compugen in a research note issued to investors on Tuesday, March 3rd. HC Wainwright analyst S. Ramakanth anticipates that the biotechnology company will post earnings per share of ($0.09) for the quarter. HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Compugen’s current full-year earnings is ($0.03) per share. HC Wainwright also issued estimates for Compugen’s Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.36) EPS.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.55. Compugen had a net margin of 48.57% and a return on equity of 55.68%. The business had revenue of $67.33 million for the quarter, compared to analysts’ expectations of $14.30 million.

A number of other brokerages have also recently issued reports on CGEN. Wall Street Zen upgraded Compugen from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Compugen in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Compugen has an average rating of “Hold” and an average target price of $4.00.

Compugen Stock Down 4.2%

Shares of CGEN opened at $2.05 on Thursday. The stock has a market cap of $182.94 million, a P/E ratio of 5.54 and a beta of 2.90. The business’s 50 day moving average price is $1.83 and its 200-day moving average price is $1.67. Compugen has a 52 week low of $1.13 and a 52 week high of $2.38.

Institutional Investors Weigh In On Compugen

Several institutional investors have recently modified their holdings of CGEN. Bank Hapoalim BM purchased a new position in shares of Compugen in the fourth quarter worth approximately $37,000. Security National Bank of Sioux City Iowa IA purchased a new stake in Compugen during the fourth quarter valued at approximately $38,000. Franklin Resources Inc. bought a new position in Compugen in the second quarter worth approximately $56,000. Osaic Holdings Inc. boosted its stake in shares of Compugen by 346.0% during the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 34,045 shares during the last quarter. Finally, WINTON GROUP Ltd purchased a new position in shares of Compugen during the 4th quarter worth $84,000. 12.22% of the stock is owned by hedge funds and other institutional investors.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.